– UK, London – Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supportingmedical innovation, today announces the appointment of Giles Kerr as a Non-Executive Director of the Company and chairman of the Board’s Audit Committee. The appointment is with immediate effect.
Giles Kerr has 36 years’ experience in finance across a broad range of industrial sectors with a particular focus on life sciences. He is currently the Director of Finance at the University of Oxford, and during his tenure he has established a successful investment office with £2.5bn under management and a £650m early-stage investment fund. He is also a Director of Oxford University Innovation Ltd, Adaptimmune Therapeutics plc, BTG plc, Senior plc and PayPoint plc.
He was previously the Chief Financial Officer of Amersham plc, acquired by GE Healthcare in 2004, and prior to that he was a partner with Arthur Andersen in the UK. He is a Fellow of Keble College, Oxford, a graduate of the University of York and a Fellow of the Institute of Chartered Accountants in England and Wales.
Jonathan Peacock, Chairman of Arix Bioscience, said: “Giles brings a strong combination of life sciences and financial experience, as well as valuable insight into the funding and commercialisation of world-class academic research. I am very pleased to announce his appointment, and we look forward to working with him.”
Giles Kerr said: “I am delighted to join the Board of Arix Bioscience, with its world-class team and a fast-developing portfolio of innovative young businesses. I look forward to working with the Board and executive team to develop important new therapies for patients and realise substantial value for shareholders.”
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.